(R)-3-((R)-5-氧代吡咯烷-2-羰基)噻唑烷-4-羧酸 | 162148-17-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (R)-3-((R)-5-氧代吡咯烷-2-羰基)噻唑烷-4-羧酸
• 中文别名: 匹多莫德杂质C
• 英文名称: (R)-3-<(R)-(5-oxo-2-pyrrolidinyl)carbonyl>-thiazolidine-4-carboxylic acid
• 英文别名: (4R)-3-[(2R)-5-oxopyrrolidine-2-carbonyl]-1,3-thiazolidine-4-carboxylic acid；Pidotimod；(R)-3-((R)-5-Oxopyrrolidine-2-carbonyl)thiazolidine-4-carboxylic acid
• CAS: 162148-17-6
• 化学式: C₉H₁₂N₂O₄S
• 分子量: 244.271
• InChiKey: UUTKICFRNVKFRG-RITPCOANSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  D-焦谷氨酸 在 sodium hydroxide 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 (R)-3-((R)-5-氧代吡咯烷-2-羰基)噻唑烷-4-羧酸
  参考文献：
  名称：

  Magni; Signorelli; Bocchiola, Arzneimittel-Forschung/Drug Research, 1994, vol. 44, # 12 A, p. 1402 - 1404

  摘要：

  DOI：

文献信息

• PIDOTIMOD FOR USE IN THE TREATMENT OF INFLAMMATION-ASSOCIATED DISEASES
  申请人：POLICHEM S.A.

  公开号：EP3146966A1

  公开（公告）日：2017-03-29

  The present invention relates to a novel use of the active ingredient Pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical NFkB pathway, such as allergic diseases, autoimmune diseases or other inflammatory diseases based on mechanisms different from allergic or autoimmune.

  本发明涉及一种活性成分匹多莫德或其立体异构体和/或其生理上可接受的盐的新型用途，用于治疗以非典型 NFkB 通路异常过度激活为特征的炎症相关疾病，如过敏性疾病、自身免疫性疾病或基于不同于过敏性或自身免疫性机制的其他炎症性疾病。
• USE OF PIDOTIMOD TO TREAT ATOPIC DERMATITIS
  申请人：Polichem SA

  公开号：EP2934520B1

  公开（公告）日：2016-11-16
• USE OF PIDOTIMOD TO TREAT PSORIASIS
  申请人：Polichem SA

  公开号：EP2934521B1

  公开（公告）日：2016-11-30
• USE OF PIDOTIMOD TO TREAT INFLAMMATORY BOWEL DISEASE
  申请人：POLICHEM SA

  公开号：US20160058739A1

  公开（公告）日：2016-03-03

  The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat inflammatory bowel disease. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, may be administered either by oral route or rectally.
• USE OF PIDOTIMOD TO TREAT IRRITABLE BOWEL SYNDROME
  申请人：POLICHEM SA

  公开号：US20160058740A1

  公开（公告）日：2016-03-03

  The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat irritable bowel syndrome. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, may be administered either by oral route or rectally.